# Long-Term Open-Label Extension Study of Oral Levosimendan

> **NCT07436689** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Tenax Therapeutics, Inc.** · enrollment: 800 (estimated)

## Conditions studied

- Pulmonary Hypertension Associated With HFpEF

## Interventions

- **DRUG:** TNX-103

## Key facts

- **NCT ID:** NCT07436689
- **Lead sponsor:** Tenax Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-03-13
- **Primary completion:** 2029-03
- **Final completion:** 2029-03
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07436689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07436689, "Long-Term Open-Label Extension Study of Oral Levosimendan". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07436689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*